checkAd
    Startseite > Aktien > RAPT Therapeutics > Nachrichten
    RAPT Therapeutics Aktie
    7,6500
     
    EUR
    +0,66 %
    +0,0500 EUR
    Letzter Kurs 12:54:22 Lang & Schwarz
    7,5500
     
    EUR
    980 STK
    Geldkurs 12:54:22
    7,7500
     
    EUR
    980 STK
    Briefkurs 12:54:22
    ISIN: US75382E1091 · WKN: A2PNYQ · USA

    Neueste Nachrichten

    RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients
    09.04.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
    07.03.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting
    05.03.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
    26.02.24 · Business Wire (engl.) · RAPT Therapeutics
    RAPT Therapeutics Announces Clinical Hold on Studies Evaluating Zelnecirnon
    20.02.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Bolsters Leadership Team with the Appointment of Nipun Davar, Ph.D., as Senior Vice President of Technical Operations
    13.02.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics to Participate in the Guggenheim Healthcare Talks 6th Annual Biotechnology Conference
    31.01.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics to Present at the 42nd Annual J.P. Morgan Healthcare Conference
    02.01.24 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Announces Publication of Phase 1a/1b Clinical Trial of Zelnecirnon (RPT193) to Treat Atopic Dermatitis in Allergy
    27.11.23 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Reports Third Quarter 2023 Financial Results
    13.11.23 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Announces Positive Data, Including Objective Response Rates and Progression-Free Survival, from its Phase 2 Trial of FLX475 in Combination with a Checkpoint Inhibitor in Patients with Advanced NSCLC
    03.11.23 · globenewswire · RAPT Therapeutics
    RAPT Therapeutics Announces Two FLX475 Presentations at the Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
    18.10.23 · globenewswire · RAPT Therapeutics